About us
Redefining cancer treatment
Oncopeptides is a science-driven biotech company developing targeted therapies for hard-to-treat cancers. With a focus on multiple myeloma, we combine cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients’ lives.
Headquartered in Stockholm, Sweden, with a pre-clinical drug development facility in Solna, Oncopeptides is listed on Nasdaq Stockholm (ticker: ONCO). Our diverse team of 75 people is united by one goal: bringing groundbreaking treatment to patients who need it most.
Our journey – more than 25 years of innovation
Oncopeptides is a science-driven biotech company developing targeted therapies for hard-to-treat cancers. With a focus on multiple myeloma, we combine cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients’ lives.
Headquartered in Stockholm, Sweden, with a pre-clinical drug development facility in Solna, Oncopeptides is listed on Nasdaq Stockholm (ticker: ONCO). Our diverse team of 75 people is united by one goal: bringing groundbreaking treatment to patients who need it most.
Oncopeptides is founded
- Oncopeptides AB is founded to further develop drugs candidates, including melflufen
- Melflufen becomes patent protected
Research & development phase
- Preclinical development phase, financed by Industrifonden and Karolinska Development AB
First clinical studies and research collaboration in the US
- Phase 1 study in solid tumors conducted at Uppsala University Hospital, Sweden
- Research collaboration established with Harvard Medical School – Dana-Farber Cancer Institute
- New freeze-dried drug formulation of melflufen is developed and patented
Important investments in the future
- Phase 1/2 study initiated in multiple myeloma patients, the study was led by Harvard Medical School – Dana-Farber Cancer Institute
- HealthCap and Industrifonden, together with a number of key individuals in the company, provide funding for the Phase 1/2 clinical program in late-stage multiple myeloma patients
- Industrifonden acquires Karolinska Development’s shares in Oncopeptides
- HealthCap becomes a shareholder
The Oncopeptides way
Breakthrough science starts with passionate people. Our inclusive culture empowers our team to challenge conventions, embrace new ideas, and transform cancer care.
Science
Data-driven, curious, innovative.
Passion
Dedicated to making a difference for patients.
Collaboration
Working across functions and borders to achieve results.
Courage
Supporting bold thinking and new ideas.
Trust
Acting with integrity and mutual respect.
Career Opportunities
Oncopeptides is a global biotechnology company committed to attracting, retaining, and developing some of the most talented people in the industry.